A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Status:
RECRUITING
Trial end date:
2029-12-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).